One of the more confused topics in midlife men's health is the relationship between BPH and prostate cancer. They share a tissue (the prostate), they share some symptoms (urinary issues), and they share an age demographic (men over 50). But they're genuinely different conditions, with different mechanisms and different implications.

BPH: the benign condition

Benign prostatic hyperplasia is non-cancerous enlargement of the prostate. The mechanism is largely hormonal — lifetime DHT exposure stimulates ongoing growth of the prostate gland. By age 50, half of men have measurable BPH; by 80, nearly all do.

BPH does not progress to prostate cancer. Having BPH does not increase your prostate cancer risk meaningfully. They're two separate conditions that happen to occur in overlapping populations.

Prostate cancer: the malignant condition

Prostate cancer is cancerous transformation of prostate cells. The biology is genuinely different — it involves cellular changes that can spread beyond the prostate. Most prostate cancers are slow-growing and never become clinically significant in the man's lifetime; some are aggressive and require active treatment.

The autopsy data is striking: roughly 30% of men in their 50s, 50% in their 70s, and 80% in their 80s have prostate cancer cells, but most never knew it during life.

How they overlap (and don't)

Symptoms: BPH typically causes urinary symptoms (slow flow, hesitancy, nocturia). Early prostate cancer typically causes no symptoms — it's usually found on screening, not symptoms. Symptomatic prostate cancer often means advanced disease.

PSA: Both conditions can elevate PSA. The level alone doesn't distinguish them. Trend over time, PSA density, free-to-total ratio, and imaging help.

Treatment: Completely different. BPH treated with watchful waiting, lifestyle, botanicals (Saw Palmetto et al), prescription medications (alpha-blockers, 5-ARIs), or surgery. Prostate cancer treated based on aggressiveness — active surveillance for slow-growing, surgery or radiation for aggressive.

The screening conversation

For men 50-70, PSA screening should be a conversation with your doctor — pros and cons, individual risk profile, preferences about over-detection. The shared decision-making framework is correct; reflexive testing or reflexive non-testing aren't.

For men with risk factors (Black ethnicity, strong family history, BRCA mutations), earlier and more frequent screening is appropriate.

What ProstaRemedy is for

ProstaRemedy is built for men with mild-to-moderate urinary symptoms — the BPH side of the story. It is not a cancer prevention or cancer treatment product. PSA monitoring and clinical screening continue independently.

The two layers — supportive supplementation and clinical screening — serve different purposes and don't substitute for each other.

The honest summary

BPH and prostate cancer are different conditions. BPH causes symptoms; cancer mostly doesn't. BPH doesn't cause cancer. Both deserve their own clinical attention and their own intervention strategies.

Get the screening conversation right with your doctor. Address symptoms with the appropriate tools. Don't conflate them.